ReviewPsychopharmacology2004
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.
Review in Psychopharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00255918 (Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine in Schizophrenia), which is not on this map. Cited by 137 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine in Schizophrenia
Who cites it
137 citing papers in PubMed, 1 synthesis or guideline pooled it, 339 citations in OpenAlex.
- A Meta-analytic Review of Auditory Event-Related Potential Components as Endophenotypes for Schizophrenia: Perspectives From First-Degree Relatives.Schizophrenia bulletin · 2016Pooled it
- A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.Psychopharmacology · 2013Trial
- Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia.Schizophrenia bulletin · 2011Trial
- Cognitive performance and cholinergic transmission: influence of muscarinic and nicotinic receptor blockade.European archives of psychiatry and clinical neuroscience · 2010Trial
- Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010Trial
- The effects of galantamine on psychopathology in chronic stable schizophrenia.Clinical neuropharmacologyTrial
- Aberrant Fear: Biological Underpinnings Relevant to Psychosis, Antipsychotic Drugs, and Psychotherapeutic Treatments, a Translational Approach.International journal of molecular sciences · 2026Review
- AAV.PHP.eB-based strategies for precise modulation of α7 nicotinic acetylcholine receptor in neurons and astrocytes in the adult mouse brain.Scientific reports · 2026Article
- The Human Alpha3 Beta2 Neuronal Nicotinic Acetylcholine Receptor Can Form Two Distinguishable Subtypes.International journal of molecular sciences · 2025Article
- Alterations in Neuronal Nicotinic Acetylcholine Receptors in the Pathogenesis of Various Cognitive Impairments.CNS neuroscience & therapeutics · 2024Review
- A comparison of visual and acoustic mismatch negativity as potential biomarkers in schizophrenia.Scientific reports · 2024Article
- α7nAChR activation in AT2 cells promotes alveolar regeneration through WNT7B signaling in acute lung injury.JCI insight · 2023Article
- Review
- Longitudinal study of inflammation and relapse in schizophrenia.Schizophrenia research · 2023Article
- Cognitive [Computational] Neuroscience Test Reliability and Clinical Applications for Serious Mental Illness (CNTRaCS) Consortium: Progress and Future Directions.Current topics in behavioral neurosciences · 2023Article
- Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update.Current neuropharmacology · 2023Review
- Manipulation of the inflammatory reflex as a therapeutic strategy.Cell reports. Medicine · 2022Review
- Marine Origin Ligands of Nicotinic Receptors: Low Molecular Compounds, Peptides and Proteins for Fundamental Research and Practical Applications.Biomolecules · 2022Review
- Attention-deficit/hyperactive disorder updates.Frontiers in molecular neuroscience · 2022Review
- Therapeutic Targeting ofPharmacological reviews · 2021Review
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
RATIONALE AND
objectiveAuditory sensory gating, a biological measurement of the ability to suppress the evoked response to the second of two auditory stimuli, is diminished in people with schizophrenia. Deficits in sensory gating are associated with attentional impairment, and may contribute to cognitive symptoms and perceptual disturbances. This inhibitory process, which involves the alpha(7) nicotinic receptor mediated release of gamma-aminobutyric acid (GABA) by hippocampal interneurons, represents a potential new target for therapeutic intervention in schizophrenia.
methodThis paper will review several lines of evidence implicating the nicotinic-cholinergic, and specifically, the alpha(7) nicotinic receptor system in the pathology of schizophrenia and the evidence that alpha(7) nicotinic receptor agonists may ameliorate some of these deficits.
resultsImpaired auditory sensory gating has been linked to the alpha(7) nicotinic receptor gene on the chromosome 15q14 locus. Single nucleotide polymorphisms of the promoter region of this gene are more frequent in people with schizophrenia. Although nicotine can acutely reverse diminished auditory sensory gating in people with schizophrenia, this effect is lost on a chronic basis due to receptor desensitization. Clozapine is able to reverse auditory sensory gating impairment, probably through an alpha(7) nicotinic receptor mechanism, in both humans and animal models with repeated dosing. The alpha(7) nicotinic agonist 3-2,4 dimethoxybenzylidene anabaseine (DMXBA) can also enhance auditory sensory gating in animal models. DMXBA is well tolerated in humans and improves several cognitive measures.
conclusionAlpha-7 nicotinic receptor agonists appear to be reasonable candidates for the treatment of cognitive and perceptual disturbances in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.